Coloplast A/S
OTC:CLPBF
Intrinsic Value
Coloplast A/S develops, manufactures, and markets medical products. [ Read More ]
The intrinsic value of one CLPBF stock under the Base Case scenario is 100.53 USD. Compared to the current market price of 129.18 USD, Coloplast A/S is Overvalued by 22%.
Valuation Backtest
Coloplast A/S
Run backtest to discover the historical profit from buying and selling CLPBF stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Coloplast A/S
Current Assets | 10.1B |
Cash & Short-Term Investments | 916m |
Receivables | 5.2B |
Other Current Assets | 3.9B |
Non-Current Assets | 38.5B |
Long-Term Investments | 65m |
PP&E | 6.1B |
Intangibles | 31.4B |
Other Non-Current Assets | 944m |
Current Liabilities | 18.9B |
Accounts Payable | 1.2B |
Accrued Liabilities | 7m |
Short-Term Debt | 4.3B |
Other Current Liabilities | 13.4B |
Non-Current Liabilities | 14.5B |
Long-Term Debt | 12.2B |
Other Non-Current Liabilities | 2.3B |
Earnings Waterfall
Coloplast A/S
Revenue
|
25B
DKK
|
Cost of Revenue
|
-8.3B
DKK
|
Gross Profit
|
16.7B
DKK
|
Operating Expenses
|
-9.8B
DKK
|
Operating Income
|
6.9B
DKK
|
Other Expenses
|
-2B
DKK
|
Net Income
|
4.9B
DKK
|
Free Cash Flow Analysis
Coloplast A/S
What is Free Cash Flow?
CLPBF Profitability Score
Profitability Due Diligence
Coloplast A/S's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Coloplast A/S's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
CLPBF Solvency Score
Solvency Due Diligence
Coloplast A/S's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Coloplast A/S's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLPBF Price Targets Summary
Coloplast A/S
According to Wall Street analysts, the average 1-year price target for CLPBF is 131.82 USD with a low forecast of 99.56 USD and a high forecast of 188.52 USD.
Shareholder Return
COLO B Price
Coloplast A/S
Average Annual Return | 8.96% |
Standard Deviation of Annual Returns | 23.37% |
Max Drawdown | -39% |
Market Capitalization | 203.7B DKK |
Shares Outstanding | 224 824 825 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
Contact
IPO
Employees
Officers
The intrinsic value of one CLPBF stock under the Base Case scenario is 100.53 USD.
Compared to the current market price of 129.18 USD, Coloplast A/S is Overvalued by 22%.